Last month, lawmakers on Massachusetts’ Joint Committee on Mental Health, Substance Use and Recovery voted to advance two psychedelic therapy bills, H.4200 and H.2203, signaling growing legislative momentum for patient-centered reform. The bills now head to the Joint Committee on Health Care Financing.
The bills move forward following extensive public testimony organized by Mass Healing, a Massachusetts-based nonprofit building a statewide network for psychedelic education, community support, and policy advocacy. At a November 10 hearing last year, nearly two dozen speakers, primarily volunteers recruited by Mass Healing, testified in support, offering powerful first-hand accounts and expert perspectives on the potential of psychedelic therapy to address PTSD, addiction, and other treatment-resistant conditions.
“I sit before you as a veteran and one of the first women to serve in combat arms positions. I’m also a former social worker and now a policy advocate working at the intersection of trauma and healing,” said Rita Graham, former Army officer, Harvard MPP, and Tillman scholar. “I’ve spent years as a researcher and a survivor of sexual violence, which is one of the most pervasive, yet ignored wounds of military service. […] Healing veterans heals communities, and Massachusetts has the opportunity to lead that change.”
There was consensus among advocates, including a former Army ranger, a 9/11 first responder, and the director of training and education at Mass General Hospital’s psychedelics research program, that psychedelics legislation should prioritize the needs of patients over corporate interests, as emphasized by the chief sponsor of H.4200, Rep. James O’Day, who testified in person.
“As someone in long-term recovery, it’s my opinion that any move towards the use of psychedelics in Massachusetts should focus exclusively on mental health and SUD treatment,” O’Day said. “And it’s important the regulation should be free from the influence of the cannabis and pharmaceutical industries. I humbly thank this committee for taking my testimony and I urge you to prioritize patient care over the profit by advancing this bill with a favorable report.”
Advocates also emphasized the need for passage of a bill exploring therapies beyond psilocybin alone, including ibogaine – a plant-derived treatment that appears capable of near-instantaneously eliminating opioid withdrawal symptoms, of particular importance for a state still reeling from the opioid crisis. Preliminary research suggests ibogaine also possesses unique neuro-regenerative properties, capable of relieving a host of psychological and physiological disorders, including PTSD and traumatic brain injury. For this reason, hundreds of Americans – particularly veterans – travel abroad each year to countries such as Mexico, where ibogaine treatment is legally available, like the former U.S. Navy SEALS featured in Netflix’s documentary “In Waves and War.” Unlike psilocybin, ibogaine is far from FDA approval, and, with a properly regulated pilot program, Massachusetts could not only join Texas and other states rapidly moving to fund ibogaine research, but with its unparalleled biomedical credentials and global partnerships, could become the world leader in ibogaine therapy.
Following the 2024 ballot campaign, Mass Healing has emerged as a leading force in the state’s psychedelic policy landscape – connecting advocates, organizing testimony, and coalition building across Massachusetts and nationwide. With multiple bills now advancing and growing legislative engagement, advocates are optimistic that Massachusetts can become a national leader in patient-centered psychedelic care.
